<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134600">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02057679</url>
  </required_header>
  <id_info>
    <org_study_id>2111</org_study_id>
    <nct_id>NCT02057679</nct_id>
  </id_info>
  <brief_title>Extended Antibiotic Therapy in Postoperative of Laparoscopic Cholecystectomy Due to Acute Cholecystitis. Is it Necessary?</brief_title>
  <official_title>Extended Antibiotic Therapy in Postoperative of Laparoscopic Cholecystectomy Due to Acute Cholecystitis. Is it Necessary?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Italiano de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Italiano de Buenos Aires</source>
  <oversight_info>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute cholecystitis (AC) is a very common complication of cholelithiasis, encountered in 20%
      of symptomatic patients.

      Nowadays laparoscopic cholecystectomy (LC) is the standard treatment in mild and moderates
      forms of diseases and antibiotic therapy in the postoperatory of these patients remains
      under discussion. However in the beginning,  AC presents itself as an steril process, the
      obstruction of the cystic duct initiates a cascade of inflammation, ischaemia and necrosis,
      as well as bacterial proliferation within the gallbladder lumen. Bactibilia was a
      significant factor associated with total, as well as infectious, operative complications.
      Regarding this, for some authors, monotherapy with amoxicillin clavulanic (AMC) would be the
      best treatment after LC in patients with mild and moderate cholecystitis without
      intraoperative complications such as bile peritonitis, cholangitis, gallbladder perforation
      or abscess. In the other hand, others do not prescribe antimicrobial treatment after surgery
      in these selected patients.

      There is controversy regarding the postoperative treatment with antibiotics in patients with
      mild and moderate cholecystitis and all the evidence about this topic.

      Therefore, investigators decided to conduct a prospective randomized study in patients
      undergoing laparoscopic cholecystectomy for acute mild and moderate cholecystitis cancer.
      The patients will be randomized to receive AMC or placebo after surgery. With this study
      investigators intend to prove that are no clinical differences in postoperative outcomes
      between patients treated with AMC and placebo.

      The primary aim of the trial is to assess that there are no benefits in the use of
      postoperative antibiotics in patients whit mild or moderate acute cholecystitis in whom a
      laparoscopic cholecystectomy was performed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of infectious postoperative complications</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence of infectious postoperative complications in patients who underwent a laparoscopic cholecystectomy due to acute mild and moderate cholecystitis, with antibiotics or placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of days of hospital stay or readmissions.</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate hospital stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of surgical reinterventions or reoperations.</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Cholecystitis</condition>
  <arm_group>
    <arm_group_label>Group A (Amoxicillin Clavulanic)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intake of active drug (Amoxicillin Clavulanic). 3 g per day divided into 3 oral intakes of 1 g each (2 pill of Amoxicillin Clavulanic every 8 hrs). This treatment will begin on  postoperative day 1 for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intake of placebo (Lactose). 1 pill of the same characteristics as Amoxicillin clavulanic every 8 hs. This will begin on postoperative day 1 for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin clavulanic</intervention_name>
    <arm_group_label>Group A (Amoxicillin Clavulanic)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 85 years old

          -  Patients with diagnose of mild or moderate acute cholecystitis.

          -  Underwent laparoscopic cholecystectomy on Italian Hospital of Buenos Aires

        Exclusion Criteria:

          -  They refuse to participate from the trial or the process of informed consent.

          -  Have known allergies or hypersensitivity to Mosapride or lactose (used for placebo).

          -  Patients with severe cholecystitis

          -  Patients with moderate cholecystitis who presents liver abscess, gallbladder abscess,
             cholangitis or bile peritonitis.

          -  Intraoperative findings like liver cancer, liver metastases, common bile duct stones
             or gallbladder carcinoma.

          -  Patients with conversion to laparotomy

          -  Previous treatment with antibiotics for more than five days.

          -  Patients with active oncological diseases, AIDS, diabetes, transplanted.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin de Santiba√±es, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Italiano de Buenos Aires</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diego Giunta, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Italiano de Buenos Aires</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pablo A. Pellegrini, MD</last_name>
    <phone>0054-011 1559679722</phone>
    <email>pablo.pellegrini@hospitalitaliano.org.ar</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>1199</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo A. Pellegrini, MD</last_name>
      <phone>54 11 59679722</phone>
      <email>pablo.pellegrini@hospitalitaliano.org.ar</email>
    </contact>
    <investigator>
      <last_name>Pablo A. Pellegrini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agustin DIetrich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oscar M. Mazza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Barcan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <reference>
    <citation>Strasberg SM. Clinical practice. Acute calculous cholecystitis. N Engl J Med. 2008 Jun 26;358(26):2804-11. doi: 10.1056/NEJMcp0800929. Review. Erratum in: N Engl J Med. 2008 Jul 17;359(3):325.</citation>
    <PMID>18579815</PMID>
  </reference>
  <reference>
    <citation>Yoshida M, Takada T, Kawarada Y, Tanaka A, Nimura Y, Gomi H, Hirota M, Miura F, Wada K, Mayumi T, Solomkin JS, Strasberg S, Pitt HA, Belghiti J, de Santibanes E, Fan ST, Chen MF, Belli G, Hilvano SC, Kim SW, Ker CG. Antimicrobial therapy for acute cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg. 2007;14(1):83-90. Epub 2007 Jan 30.</citation>
    <PMID>17252301</PMID>
  </reference>
  <reference>
    <citation>Yildiz B, Abbasoglu O, Tirnaksiz B, Hamaloglu E, Ozdemir A, Sayek I. Determinants of postoperative infection after laparoscopic cholecystectomy. Hepatogastroenterology. 2009 May-Jun;56(91-92):589-92.</citation>
    <PMID>19621660</PMID>
  </reference>
  <reference>
    <citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.</citation>
    <PMID>3558716</PMID>
  </reference>
  <reference>
    <citation>Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santiba√±es E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009 Aug;250(2):187-96.</citation>
    <PMID>19638912</PMID>
  </reference>
  <reference>
    <citation>Yokoe M, Takada T, Strasberg SM, Solomkin JS, Mayumi T, Gomi H, Pitt HA, Gouma DJ, Garden OJ, B√ºchler MW, Kiriyama S, Kimura Y, Tsuyuguchi T, Itoi T, Yoshida M, Miura F, Yamashita Y, Okamoto K, Gabata T, Hata J, Higuchi R, Windsor JA, Bornman PC, Fan ST, Singh H, de Santibanes E, Kusachi S, Murata A, Chen XP, Jagannath P, Lee S, Padbury R, Chen MF; Tokyo Guidelines Revision Committee. New diagnostic criteria and severity assessment of acute cholecystitis in revised Tokyo Guidelines. J Hepatobiliary Pancreat Sci. 2012 Sep;19(5):578-85. doi: 10.1007/s00534-012-0548-0.</citation>
    <PMID>22872303</PMID>
  </reference>
  <reference>
    <citation>Kanafani ZA, Khalif√© N, Kanj SS, Araj GF, Khalifeh M, Sharara AI. Antibiotic use in acute cholecystitis: practice patterns in the absence of evidence-based guidelines. J Infect. 2005 Aug;51(2):128-34. Epub 2005 Jan 20. Review.</citation>
    <PMID>16038763</PMID>
  </reference>
  <reference>
    <citation>Grande M, Torquati A, Farinon AM. Wound infection after cholecystectomy. Correlation between bacteria in bile and wound infection after operation on the gallbladder for acute and chronic gallstone disease. Eur J Surg. 1992 Feb;158(2):109-12.</citation>
    <PMID>1350211</PMID>
  </reference>
  <reference>
    <citation>Galili O, Eldar S Jr, Matter I, Madi H, Brodsky A, Galis I, Eldar S Sr. The effect of bactibilia on the course and outcome of laparoscopic cholecystectomy. Eur J Clin Microbiol Infect Dis. 2008 Sep;27(9):797-803. doi: 10.1007/s10096-008-0504-8. Epub 2008 Mar 28.</citation>
    <PMID>18369670</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 10, 2014</lastchanged_date>
  <firstreceived_date>February 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Italiano de Buenos Aires</investigator_affiliation>
    <investigator_full_name>Diego Hernan Giunta, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Acute cholecystitis.</keyword>
  <keyword>Amoxicillin clavulanic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholecystitis</mesh_term>
    <mesh_term>Acalculous Cholecystitis</mesh_term>
    <mesh_term>Cholecystitis, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
